Theravance Biopharma, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Dean J. Mitchell

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Dean J. Mitchell”): 42,557,257 for, 297,316 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,427,589 for, 7,544 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Deepika R. Pakianathan

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 41,936,019 for, 918,543 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,186,927 for, 248,206 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Donal O'Connor

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 42,535,463 for, 319,110 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,429,795 for, 5,337 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Laurie Smaldone Alsup

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Laurie Smaldone Alsup”): 42,725,649 for, 124,187 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,428,399 for, 6,734 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Rick E Winningham

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 42,474,538 for, 377,274 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,431,473 for, 3,660 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Susannah Gray

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 42,231,530 for, 618,306 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 8,224,672 for, 210,461 against, 11,536 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Approve the non-binding advisory resolution regarding the compensation of our named executive officers.

Theravance Biopharma, Inc.’s own tally for this item (“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”): 42,631,324 for, 221,196 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 8,437,017 for, 11,536 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 166 managers: 26,176,183 for, 99,669 against, 1,741 abstained, 1,214 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Theravance Biopharma, Inc.’s own tally for this item (“Proposal 2: Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified”): 46,471,340 for, 572,896 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,431,169 for, 6,401 against, 11,536 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.